CLINICAL SAFETY OF TREATMENT WITH ZILEUTON, 5-LOX INHIBITOR, DURING ACUTE INFLAMMATORY REACTION IN NILE TILAPIA (Oreochromis niloticus)

Zileuton is an inhibitor of the 5-lipoxygenase enzyme that transforms essential fatty acid (EFA) substrates into leukotrienes (LTB4, LTC4, LTD4 and LTE4), but little known about use this drug in teleost fish. Therefore, objective study was to evaluate clinical safety treatments with 2,25 mg 4,50 zileuton/Kg -1 (bodyweight), administered orally diet, through biochemical hematological analysis during acute inflammatory reaction Nile tilapia ( Oreochromis niloticus ), induced by Aeromonas hydrophila bacterins. The used eighty tilapias, conditioned 20 tanks (n=4), constituting following treatments: T0 (control), T1 (2,25 zileuton) T2 (4,50 zileuton), being sampled eight animals per treatment three periods: 6, 24 48 hours post-inoculation, a 10th group consisting fish without any type stimulus obtain reference values. In order determine blood count serum biochemical, it necessary collect samples. hematology results treated zileuton did not reveal alterations between subjected different control (T0). liver cytotoxicity tilapias significant (p≥0,05) AST ALT enzymatic activity. total protein showed decrease at HPI. As time progressed, indicated albumin levels for determination biochemichal creatinine, cholesterol, triglycerides, glucose differ statistically treatments. observed analyzes allows conclude orally, doses mg/Kg (body weight) demonstrated be clinically safe.